Format

Send to

Choose Destination
Bioorg Med Chem Lett. 2009 Jul 1;19(13):3664-8. doi: 10.1016/j.bmcl.2009.03.165. Epub 2009 Apr 17.

Second generation of BACE-1 inhibitors. Part 1: The need for improved pharmacokinetics.

Author information

1
Neurology and Gastrointestinal Centre of Excellence for Drug Discovery, GlaxoSmithKline R&D, New Frontiers Science Park, Third Avenue, Harlow, Essex CM19 5AW, United Kingdom.

Abstract

Inhibition of the aspartyl protease BACE-1 has the potential to deliver a disease-modifying therapy for Alzheimer's disease. We have recently disclosed a series of transition-state mimetic BACE-1 inhibitors showing nanomolar potency in cell-based assays. Amongst them, GSK188909 (compound 2) had favorable pharmacokinetics and was the first orally bioavailable inhibitor reported to demonstrate brain amyloid lowering in an animal model. In this Letter, we describe the reasons that led us to favor a second generation of inhibitors for further in vivo studies.

PMID:
19428244
DOI:
10.1016/j.bmcl.2009.03.165
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center